Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-viral compositions containing pikfyve inhibitors and use thereof

a technology of antiviral compositions and inhibitors, which is applied in the field of antiviral compositions, can solve the problems of no approved therapies, difficult diagnosis confirmation in the field, and general limitations in evd care, so as to prevent or ameliorate a cytokine storm, reduce the viral load of the subject, and reduce the rate of viral replication

Inactive Publication Date: 2020-11-19
AI THERAPEUTICS INC
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a method of treating a subject with a PIKfyve inhibitor, which can prevent or reduce a cytokine storm, inhibit viral replication, and lower the viral load. The treatment involves administering a daily dose of apilimod, which is a PIKfyve inhibitor composed of 70 to 1000 mg. The dose is effective to achieve a plasma concentration of the inhibitor ranging from 50 to 1000 nM. The technical effect of this treatment is to provide a beneficial effect on the subject's health by preventing or treating various symptoms associated with cytokine storms and viral infections.

Problems solved by technology

Over the clinical course of Ebola, patients can develop fulminant septic shock and coagulopathy which can subsequently lead to death.
Several diagnostic tests are available for Ebola; including RT-PCR and ELISA tests (Burd, 2015; Bishop 2014); however, none of these tests are available in a non-hospital setting; therefore, making confirmation of the diagnosis difficult in the field.
EVD care is generally limited to supportive care including administration of IV fluids, maintenance of oxygen status and blood pressure and treatment other underlying conditions or organ dysfunction or failure.
Currently, there are no approved therapies for EVD.
The efficacy of both of these experimental agents has yet to be established in controlled clinical trials.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-viral compositions containing pikfyve inhibitors and use thereof
  • Anti-viral compositions containing pikfyve inhibitors and use thereof
  • Anti-viral compositions containing pikfyve inhibitors and use thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

is a Highly Selective Binder of PIKfyve Kinase

[0098]Protein kinase profiling of apilimod was conducted to identify kinase targets (DiscoveRx, Fremont, Calif.). A dissociation constant (Kd) study was performed using apilimod at increasing concentrations (0.05-3000 nM) against PIKfyve, a known target of apilimod. The experiment was performed in duplicate and the Kd was determined to be 0.075 nM (range 0.069-0.081 nM) (see FIG. 1).

[0099]Apilimod was also screened against a comprehensive panel of kinases (PIKfyve not included). In total, 456 kinases, including disease-relevant kinases, were assayed for their ability to bind with apilimod. The screening concentration of apilimod was 1 mM, a concentration that is >10,000 times greater than the Kd for apilimod against PIKfyve. The results from the screen showed that apilimod did not bind to any of the 456 kinases tested.

[0100]Together, these results demonstrate that apilimod binds with high selectivity to a single cellular kinase, PIKfyve....

example 2

Induces Vacuolization and Disrupts Intracellular Traficking in Cells

[0101]Apilimod has been demonstrated to be a potent and specific inhibitor of the phosphoinositide kinase PIKfyve, an enzyme that binds to PI(3)P and catalyzes the formation of the lipid second messengers PI(3,5)P2 and PI(5)P. PIKfyve is associated with the cytosolic leaflet of early endosomes and its activity is required for endomembrane homeostasis, endolysosomal function and proper retrograde transport from the endosome to the trans-Golgi network. Introduction of a kinase dead mutant into cells induces a swollen vacuole phenotype that can be rescued by the injection of PI(3,5)P2. Inhibition of PIKfyve by pharmacological methods as well as RNAi also produces swollen vacuoles and disruption of endomembrane dynamics. It has been discovered that pharmacological disruption of PIKfyve with apilimod induces selective lethality of specific cancer cell lines through disruption of intracellular trafficking (see FIG. 2).

example 3

n of in vivo Anti-Ebola Activity in Humans

[0102]Inhibition of cancer cell proliferation and inhibition of Ebola virus infection share a common mechanism i.e. inhibition of PIKfyve leading to vacuole formation and loss of intracellular trafficking. In the above clinical study, the trough TAEC values were greater than 25 mg / mL (60 nM). Since vacuole formation in cells at apilimod concentrations as low as 20 nM have been observed, one could conclude that oral administration of apilimod free base at doses ranging from 70 to 1000 mg / day should provide continuous PIKfyve inhibition to maintain vacuolization of cells and block Ebola infection in clinical therapy in patients.

[0103]Furthermore, it was shown in female Balb / c mice, a strain often used for in vivo Ebola infection studies, that constant infusion of apilimod as the bis-mesylate salt, using subcutaneously implanted osmotic mini-pumps (e.g. Alzet models 1007D, 15 mg / kg / day; model 2001, 30 mg / kg / day; vehicle: 25% DMSO, 25% Cremaphor...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to compositions containing a PIKfyve inhibitor, preferably apilimod, APY0201 or YM-201636, most preferably apilimod, for use in treating or preventing viral infections, preferably Ebola or Marburg virus infections. It also relates to a pharmaceutical pack or kit comprising apilimod and at least one additional anti-viral agent.

Description

RELATED APPLICATIONS[0001]This application is a continuation of U.S. patent application Ser. No. 15 / 545,337 filed on Jul. 21, 2017, which is a national stage entry, filed under 35 U.S.C. § 371, of International Application No. PCT / US2016 / 014254, filed on Jan. 21, 2016, which claims priority to U.S. Patent Application Ser. No. 62 / 107,263, filed on Jan. 23, 2015, the contents of which are hereby fully incorporated by reference.FIELD OF THE INVENTION[0002]The present invention relates to anti-viral compositions and methods of using same.BACKGROUND OF THE INVENTION[0003]Many viruses enter the cell via endocytosis and utilize the cell's the endosomal network as a means to infiltrate the cell and replicate. For example, viral entry into cells may be mediated by a viral glycoprotein (GP), which attaches viral particles to the cell surface, delivers them to endosomes, and catalyzes fusion between viral and endosomal membranes. For example, Rab9 GTPase was shown to be required for replicatio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/5377A61K31/00C12N15/113C07K16/10A61K45/06A61K31/713A61K38/21A61K39/395
CPCA61K45/06C07K16/10C12N15/1131A61K31/5377A61K38/21A61K39/39575A61K31/713C07K2317/76A61K31/00C12N2310/14A61P31/12A61P31/14A61K2300/00
Inventor LICHENSTEIN, HENRIROTHBERG, JONATHAN M.BEEHARRY, NEILBECKETT, PAULLANDRETTE, SEANCONRAD, CHRIS
Owner AI THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com